Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cereno Scientific shares speakers and program for its Capital Markets Day on August 30, 2023

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced the speakers and program for the company’s Capital Markets Day on August 30, 2023. We invite analysts, investors, and financial media to join us for insights into our strategy and operations.At the Capital Markets Day, executive management and external collaborators will provide an update on Cereno’s pipeline, clinical and preclinical development, and growth strategy. The speakers and their associated speaking slots include:   ·

Katalysen Ventures celebrates milestone partnership between portfolio company Meal Makers and Sodexo

Katalysen Ventures is delighted to announce that portfolio company Meal Makers has joined forces with Sodexo, a renowned global service company serving over 100 million people daily across 53 countries, to tackle the pressing issue of food waste.In an effort to combat the alarming amount of food that goes to waste each day, Sodexo and Meal Makers have embarked on an innovative collaboration that marries technology with purpose. This collaboration will empower purchasers at Sodexo's restaurants by providing them access to Meal Makers' groundbreaking digital marketplace. Through this platform,

Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million

Stockholm, Sweden - August 28, 2023 – Biosergen AB ("Biosergen" or the “Company") today announces the outcome of the exercise of warrants series TO2, which were issued in connection with the Company’s rights issue of units on Nasdaq First North Growth Market in October 2022. In total, 8,258,203 warrants series TO2, corresponding to approximately 96.1 percent of the total number of outstanding warrants series TO2, were exercised for subscription of 8,258,203 shares at an exercise price of SEK 0.66 per share. Biosergen will thereby receive approximately SEK 5.5 million before issuing costs.

Secop Group Holding GmbH reports Q2-2023 financial results

On 28 August 2023, Secop Group Holding GmbH announced its financial results for the second quarter 2023. After a difficult first quarter, Secop experienced an overall recovery in Q2-2023. While Net Sales remained below the respective quarter of 2022, Internal Adjusted EBITDA, Net Income and Operating Cash-Flow clearly exceeded the respective previous year’s period figures.Net Sales of Q2-2023 reached EUR 65,5m, which undercut previous year’s period Net Sales by EUR 5,0m (PY*: EUR 70,5m) due to a lower demand in some regions and segments following difficult political and economic

Cybersecurity often out of sync with business goals

Aligning cybersecurity with business outcomes is a challenge facing nearly all businesses, according to a study published by WithSecure.Helsinki, Finland – August 28, 2023: 97% of respondents’ organizations face challenges in trying to align cybersecurity priorities with business outcomes, according to a commissioned study conducted by Forrester Consulting on behalf of WithSecure ™ (formerly known as F-Secure Business). According to the study’s spotlight, the challenges fall into three categories: conflicting goals, complexity of environment, and privacy

Panel talk about Inify’s second quarter 2023

The second quarter of 2023 marked an important milestone for Inify Laboratories - the opening of the laboratory in Solna/Stockholm to offer prostate cancer diagnostic services for urology clinics and their patients.Listen to CEO Fredrik Palm and Laboratory Manager Emelie Edvigsson in this panel talk, led by Ole Eikeland, where they explain some of the success factors for Inify's first laboratory. Some highlights include the positive customer feedback, the strategic partnerships and the importance of a tailor-made Laboratory Information System, LIS, to support the workflow instead of forcing

Danske Hypotek AB: Interim Report January-June 2023

First half-year in briefJanuary – June 2023 (comparison with January – June 2022 in parentheses)· Operating profit was SEK 476.7 million (501.0 million) · Net interest income amounted to SEK 467.5 million (635.1 million) · Costs comprised SEK 112.1 million (126.6 million) · Credit losses amounted to SEK 1.5 million refers to reversals of previous reservations. For the corresponding period in 2022 reversals amounted to SEK 16.0 million · Return on equity was 10.2 % (11.8 %) · The CET1 capital ratio was 18.0 % (16.0 %) · Danske Hypotek’s covered bonds have the highest

Axactor ASA – Notice of exercise of call option

We refer to the stock exchange notice published 25 August 2023 regarding the successful placement of a new senior unsecured bond issue. Axactor ASA has today notified Nordic Trustee AS that it will exercise the call option to redeem all outstanding bonds (EUR 200,000,000) under its senior unsecured bond issue (with ISIN NO0010914666) and each Bondholder is hereby given notice thereof. The bonds were issued 12 January 2021 with maturity 12 January 2024. The exercise of the call option is conditional upon certain conditions as set out in the Call Option Notice being satisfied no later than

Nordea Bank Abp flagging notification: BlackRock Inc.’s shareholding decreases below threshold of five percent

Nordea Bank AbpStock exchange release – Major shareholder announcements28 August 2023 at 15.00 EET BlackRock, Inc.'s indirect shareholding of Nordea Bank Abp’s shares and voting rights has decreased below the threshold of five percent, according to a notification Nordea received on 28 August 2023 under Chapter 9, Section 10 of the Securities Markets Act (SMA). The threshold was crossed on 25 August 2023. The total number of shares and voting rights in Nordea Bank Abp is 3,569,745,018. Total positions of BlackRock, Inc. and its funds according to the notification: +-----------

Invitation to Wärtsilä’s Capital Markets Day 2023

Wärtsilä Corporation, press release, 28 August 2023 at 15:00 EESTInvitation to Wärtsilä’s Capital Markets Day 2023 Wärtsilä invites investors, analysts and representatives from banks and media to Wärtsilä's Capital Markets Day, which will be held on Thursday, 9 November 2023 at 13:00–16:30 (EET) via webcast. Wärtsilä’s President & CEO Håkan Agnevall together with members of the Board of Management will host the event. During the day, Wärtsilä's management will provide current information on the company's business operations, strategy, and financial development. The event will be held

Immedica to present new pegzilarginase data at the SSIEM Annual Symposium 2023

Stockholm, August 28, 2023 Immedica today announces the presentation of new data at the SSIEM (Society for the Study of Inborn Errors of Metabolism) annual symposium taking place in Jerusalem, Israel. The presentation highlights important long-term patient-level data on pegzilarginase, a potential first disease modifying treatment for arginase 1 deficiency (ARG1-D). Anders Edvell, Immedica CEO commented: “We are very pleased to be able to present this new patient-level data that demonstrates long-term clinical outcomes of pegzilarginase for the treatment of ARG1-D, a disease where the

Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial

Oslo, 28 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has completed recruitment of 20 patients in the ATLAS-IT-05 trial - a trial evaluating LTX-315, Lytix’ lead drug candidate.The ATLAS-IT-05 trial is designed to assess the efficacy of LTX-315 in patients with advanced melanoma, who are refractory to treatment with anti-PD-1/PD-L1 inhibitors. LTX-315 is being studied in combination with the immune checkpoint inhibitor pembrolizumab, which blocks tumor cells’ ability to prevent the body’

DecideAct signs contract with Animal Protection Denmark

Animal Protection Denmark (Dyrenes Beskyttelse) has chosen DecideAct to provide a digital platform and expertise to support the execution of their 2030 strategy. As Denmark's leading animal protection organization, Animal Protection Denmark helps animals in need, stops animal abuse, and fights for a respectful and sustainable relationship between animals, humans, and nature.Animal Protection Denmark is a voluntary organization that is mainly funded by private donations. The association has just under 70,000 members, 250 employees, and a large network of volunteers throughout Denmark.The

Notification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä Corporation

Wärtsilä Corporation, flagging notification, 28 August 2023 at 14:00 EESTNotification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä CorporationBlackRock, Inc. has informed Wärtsilä Corporation that it has crossed above the 5% disclosure limit on total holding in shares and voting rights on 25 August 2023. Following the transaction, BlackRock, Inc. owns 5.11% of Wärtsilä’s shares and voting rights, while its total holding in Wärtsilä Corporation corresponds to 5.27%. Total position of BlackRock, Inc. and its funds subject to

Fortaco Group Holdco Plc’s Half-Year Review January-June 2023 (unaudited, IFRS): Growth and acquisitions continued

Fortaco Group Holdco Plc Stock Exchange Release 28.8.2023 at 14:00 p.m.This release is a summary of Fortaco Group Holdco Plc’s Half-Year Review January-June 2023. The full release is attached and available on our website at https://investors.fortacogroup.com. Figures in parentheses refer to the corresponding period of the previous year, unless otherwise stated. Highlights: April-June 2023  · Net sales was EUR 95.9 million (comparable net sales growth 14.8 per cent). · Recurring EBITDA was EUR 8.7 million (9.1 per cent of net sales, comparable growth in recurring EBITDA -2.2

Clinical Laserthermia Systems and Focalyx enters co-marketing agreement for image-guided focal laser ablation of prostate cancer

Lund, Sverige – Clinical Laserthermia Systems AB (publ) (“CLS”) today announced that their US subsidiary, CLS Americas, has entered a co-marketing agreement with Focalyx  to sell and market an integrated, minimally invasive, fusion-guided focal laser ablation treatment for low-to-intermediate risk prostate cancer patients.CLS’s TRANBERG® Thermal Therapy System and the Focalyx® Fusion image-guidance system will initially be offered to urology clinics under a Mobile Service Provider (MSP) Agreement that includes consumable accessories, training, and on-site clinical

NYAB Plc's half-yearly report 2023 – latest videos and management views

NYAB Plc’s half-yearly report was published on Friday 25th of August at 10 a.m. EET, and the management webcast was arranged in the afternoon. Later in the afternoon, CEO Johan Larsson shared his reflections on the first half of the year and the markets in general, in a video interview with Aapeli Pursimo from Inderes, a Finnish equity analyst company.NYAB Plc’s half-yearly report was published on Friday 25th of August at 10 a.m. EET, and the management webcast was arranged in the afternoon, with a headline Strong growth and development despite macroeconomic headwinds. Later in the

Teleste joins the UN Global Compact network

Teleste is committed to the world's largest corporate responsibility initiative, the UN Global Compact. Participation in the community continues Teleste's responsibility work and provides a functional framework for deepening it.Turku, Finland – 28 August 2023 – The Global Compact is a corporate responsibility initiative established by the UN in 2000, which promotes the ecological, social, and financial responsibility of companies and communities. With its more than 23,000 participants, the initiative commits to principles  and goals

ISR’s, SARS-CoV-2 dry powder nasal - vaccine booster candidate, ISR52, demonstrates superior immune response, in mouse model challenge studies compared to subcutaneous injection of this vaccine.

The preclinical SARS-CoV-2 vaccine collaboration project between ISR (Immune System Regulation AB)  and Professor Ali Mirazimi, adjunct professor at the Department of Laboratory Medicine, Karolinska Institutet has now been published in the journal Vaccine.The mucosal immune system is the largest component of the entire immune system, having evolved to provide protection at the main sites of infectious threat: the mucosae. As SARS-CoV-2 initially infects the upper respiratory tract, its first interactions with the immune system must occur predominantly at the respiratory mucosal surfaces,

Property owners should react to the energy transition now – hesitation can be costly

Caverion Corporation Article 28 August 2023 at 13.00Property owners should react to the energy transition now – hesitation can be costly The increased electricity prices have caused many to realise that maybe the energy situation last winter was not exceptional after all. Investing into property modernisations should be made systematically and in a timely manner, as delaying them might lead to resource problems and increased costs in the future. When planning investments for properties, it's worth considering the energy transition and revisiting the discussions from last winter. "

First patient enrolled in Stayble Therapeutics' Phase 1b clinical study in herniated discs

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the first patient has been enrolled in the Company's Phase 1b clinical study with STA363 for treatment of herniated discs. STA363 for Herniated discs is the second indication for the drug candidate STA363, which is also undergoing a clinical study in degenerative disc disease. Stayble has successfully completed a Phase 1b study in degenerative disc disease and is currently in the final phase of an ongoing Phase 2b study.The Phase 1b study for herniated discs is a randomized, double-blinded, placebo-controlled study

Glaston Oyj - Managers' Transactions

Glaston Corporation     Stock Exchange Release, Managers' Transactions  28.8.2023 at 12.00Glaston Oyj Abp - Managers' Transactions____________________________________________Person subject to the notification requirementName: Veli-Matti ReinikkalaPosition: Member of the Board/Deputy member Issuer: Glaston Oyj AbpLEI: 743700V3I7CLI3DJ8L62Notification type: INITIAL NOTIFICATIONReference number: 37070/5/4 ____________________________________________Transaction date: 2023-08-25Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000369657Nature of

Ikano Bank AB (publ) Interim Report 30 June 2023

“Together we are making a comprehensive change, creating a more commercially relevant bank with profitable growth, where we provide our customers with accessible financial services. It involves a technical, organisational and cultural change at Ikano Bank, and our transformation continues in full force. At the same time, we are experiencing troubled and challenging times, with rising inflation, higher interest rates and the war in Ukraine, which further reinforces the need for simple financial services for the many people. The investments that have weighed on our results in recent years are

There are no items matching the current filter
There are no more items matching the current filter
Back to top